🔍

CIPLA - Cipla

📊 NSE: CIPLA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 21:05

📢 Recent Corporate Announcements

Cipla USA Initiates Recall of Lanreotide Injection Leading to Temporary Supply Shortage

🔴 NEGATIVE ⭐ 6/10

REGULATORY 📅 09 Mar 2026, 10:50 PM

Cipla Limited's wholly owned subsidiary, Cipla USA Inc., has announced a recall of all unexpired batches of Lanreotide Injection. This decision was made following discussions with Pharmathen International S.A. and will result in a temporary lack of supply for this product in the market. The recall follows previous disclosures made by the company in January and February 2026, indicating an ongoing regulatory or quality issue. This development is expected to impact the company's US revenue from this specific product line in the near term.

Cipla USA Inc. to recall all unexpired batches of Lanreotide Injection from the market.
The recall will lead to a temporary lack of supply for the injection in the US market.
Decision follows discussions with partner Pharmathen International S.A. and previous updates in early 2026.
The move is a disclosure under Regulation 30 of SEBI Listing Regulations.

💡 Investors should monitor the duration of the supply disruption and assess the potential impact on Cipla's US generic revenue. Watch for further management commentary on the specific reasons behind the recall and the timeline for market re-entry.

Cipla's ESG Rating Revised Downward to 65 from 66 by NSE Sustainability

🔴 NEGATIVE ⭐ 4/10

REGULATORY 📅 26 Feb 2026, 05:20 PM

NSE Sustainability Ratings & Analytics Limited has revised Cipla's ESG rating for FY 2024-25 from 66 to 65. This marginal downgrade is attributed to a product recall initiated by the company's wholly owned subsidiary, Cipla USA Inc., in January 2026. While the numerical change is small, it reflects the impact of operational quality issues on the company's sustainability profile. The disclosure was made following SEBI's updated reporting requirements for ESG rating providers.

ESG rating for FY 2024-25 revised from 66 to 65 by NSE Sustainability Ratings & Analytics Limited
Downgrade linked to a product recall by Cipla USA Inc. occurring in January 2026
Communication regarding the rating change was received on February 25, 2026
Disclosure complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations

💡 Investors should monitor the scale of the US product recall and any subsequent FDA actions, as these pose a higher risk than the marginal ESG rating change. The rating drop is minor and unlikely to impact institutional holdings significantly in the short term.

Cipla to Attend Kotak Securities Conference on February 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 07:24 PM

Cipla Limited has announced its participation in an upcoming institutional investor meeting scheduled for February 23, 2026. The company will be attending the Kotak Securities Conference in Mumbai for in-person interactions. This disclosure is a routine compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015. Such meetings are standard practice for large-cap companies to engage with the analyst community regarding business updates.

Meeting scheduled for February 23, 2026, in Mumbai
Participation in the Kotak Securities Conference
In-person meeting format with analysts and institutional investors
Compliance filing submitted on February 17, 2026, under SEBI LODR

💡 No immediate action is required as this is a routine investor relations event. Investors should watch for any post-event management commentary or analyst notes that may emerge following the conference.

Cipla's InvaGen Facility Receives 2 USFDA Observations Post-Inspection

🔵 WATCH ⭐ 6/10

REGULATORY 📅 10 Feb 2026, 08:42 AM

Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, underwent a Pre-Approval Inspection (PAI) by the USFDA at its Hauppauge, New York facility from February 2 to February 9, 2026. Upon conclusion, the facility was issued 2 inspectional observations in Form 483. The company has committed to addressing these observations comprehensively within the stipulated timeframe. This inspection is critical as it is a Pre-Approval Inspection, which directly impacts the timeline for new product launches in the US market.

USFDA conducted a Pre-Approval Inspection (PAI) at the InvaGen facility in Hauppauge, New York.
The inspection lasted 8 days, concluding on February 9, 2026.
The facility received 2 observations in Form 483 following the audit.
InvaGen Pharmaceuticals is a 100% wholly-owned subsidiary of Cipla Limited.
Cipla intends to work closely with the USFDA to resolve the issues within the required timeline.

💡 Investors should monitor for further updates regarding the severity of the 2 observations, as successful resolution is necessary for upcoming product approvals. The low number of observations is generally manageable, but any escalation could delay US market expansion plans.

Cipla Announces Conclusion of GST Inspection by Maharashtra Authorities

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 08 Feb 2026, 02:50 PM

Cipla Limited has reported the conclusion of a GST inspection and search by the Deputy Commissioner of State Tax, Maharashtra, which ended on February 7, 2026. The search was conducted under Section 67 of the Maharashtra Goods & Service Tax Act, 2017, following a prior notification on February 5. The company has provided all requested documents and clarifications, and no official document or notice of violation has been issued by the authorities. Management has explicitly stated that there is no material impact on the company's financials, operations, or other activities due to this event.

GST inspection by Maharashtra State Tax authorities concluded on February 7, 2026, at 22:00 hours IST.
The search was conducted under Section 67 of the Maharashtra Goods & Service Tax Act, 2017.
No official document or violation notice has been issued to the company following the inspection.
Management confirms no material impact on the company's financial or operational performance.

💡 Investors should treat this as a routine regulatory update as no financial liability or penalty has been disclosed. No immediate action is required, but keep a watch for any future tax demand notices resulting from this search.

Cipla Faces GST Inspection at Maharashtra Facilities; Operations Unaffected

🔵 WATCH ⭐ 6/10

REGULATORY 📅 05 Feb 2026, 06:46 PM

The Maharashtra Goods & Service Tax Department initiated inspection and search proceedings at Cipla's facilities and offices on February 5, 2026. The search, conducted under Section 67 of the MGST Act, focuses on tax payments, input tax credit claims, and refunds. While the proceedings are ongoing, the company has stated there is currently no financial impact or disruption to operations. Investors should monitor for any subsequent tax demands or penalties that might arise from this investigation.

GST Department, Maharashtra initiated search proceedings on February 5, 2026, at 12:30 PM.
Investigation covers tax payments, input tax credit (ITC) claims, and refund processes.
Action taken under Section 67(1) and 67(2) of the Maharashtra GST Act, 2017.
Company reports no immediate financial impact or operational disruption due to the search.

💡 Monitor for further disclosures regarding any tax demand notices or penalties resulting from this inspection. No immediate sell-off is warranted as operations remain normal.

Cipla to Participate in Axis Capital India Conference on Feb 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 05:35 PM

Cipla Limited has notified the exchanges regarding its participation in the Axis Capital India Conference on February 11, 2026. The meeting will be held in person in Mumbai with various institutional investors and analysts. This disclosure is a routine requirement under Regulation 30 of the SEBI (LODR) Regulations, 2015. Such interactions typically focus on the company's business outlook and industry trends rather than specific financial results.

Meeting date set for February 11, 2026, at the Axis Capital India Conference.
The interaction will be in-person with institutional investors in Mumbai.
The announcement was officially filed with BSE and NSE on February 4, 2026.
The schedule is subject to change due to unforeseen circumstances.

💡 Investors should look for any investor presentations uploaded to the exchange following the meeting for updates on the company's strategy.

Cipla Appoints Arun Kakatkar as Global Chief People Officer Effective March 17, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 02 Feb 2026, 10:09 AM

Cipla Limited has announced the appointment of Mr. Arun Kakatkar as its Global Chief People Officer and Senior Management Personnel, starting March 17, 2026. Mr. Kakatkar is a seasoned leader with a background in engineering and an MBA, having previously held senior roles at Microsoft Corporation and TE Connectivity. This appointment, approved by the Board on February 2, 2026, is aimed at strengthening the company's organizational and leadership capabilities. The move reflects Cipla's focus on fostering a strong global culture and sustainable business outcomes through experienced human resources leadership.

Mr. Arun Kakatkar appointed as Global Chief People Officer effective March 17, 2026
Brings extensive experience from global firms including Microsoft Corporation and Kalyani Group
Board approval for the appointment was finalized on February 2, 2026
The role is designated as Senior Management Personnel under SEBI regulations

💡 This is a routine senior management appointment and requires no immediate action from investors. Monitor for any broader shifts in corporate strategy that may follow this leadership change.

Cipla Allots 8,879 Equity Shares Under ESOP and ESAR Schemes

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Jan 2026, 06:25 PM

Cipla Limited has allotted 8,879 fully paid-up equity shares of face value INR 2 each on January 28, 2026. This allotment is a result of employees exercising their options under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. Consequently, the company's total paid-up share capital has increased to INR 1,61,55,61,354. The total number of equity shares outstanding now stands at 80,77,80,677.

Allotment of 8,879 equity shares of INR 2 face value each
Shares issued under ESOS 2013-A and ESAR Scheme 2021
Total paid-up capital increased to INR 161.55 crore
Total outstanding equity shares reached 80,77,80,677
Allotment approved by the Operations and Administrative Committee on Jan 28, 2026

💡 This is a routine administrative update with negligible equity dilution. No action is required from investors as it does not impact the company's fundamental valuation.

Cipla Q3 FY26: Revenue flat at Rs 7,074 Cr; EBITDA margin dips to 17.7% on Revlimid decline

🔴 NEGATIVE ⭐ 9/10

EARNINGS 📅 27 Jan 2026, 07:41 PM

Cipla reported flat year-on-year revenue of Rs 7,074 crores for Q3 FY26, primarily impacted by a sharp decline in generic Revlimid sales. The One-India business remained a bright spot with 10% growth, while the North America segment recorded $167 million in revenue. Profitability was pressured, with EBITDA margins falling to 17.7% and PAT at Rs 676 crores, which included a Rs 276 crore exceptional item for labor code changes. Management lowered the full-year FY26 EBITDA margin guidance to approximately 21% due to Lanreotide supply disruptions and increased R&D investments.

Revenue stood at Rs 7,074 crores (flat YoY) with EBITDA margin at 17.7% excluding other income.
One-India business grew 10% YoY, with the respiratory segment crossing Rs 5,000 crores in IPM.
Lanreotide supply is temporarily paused due to partner FDA issues, with resupply expected only in H1 FY27.
R&D spending increased by 37.4% YoY to Rs 494 crores (7% of revenue) to support the future pipeline.
Net cash position remains strong at Rs 10,229 crores despite dividend payments and acquisitions.

💡 Investors should be cautious due to the lowered margin guidance and Lanreotide supply issues, though the strong India growth and healthy cash balance provide long-term support. Monitor the progress of the Indore facility re-inspection and the transition to new leadership under Achin Gupta.

Cipla Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jan 2026, 07:14 PM

Cipla Limited has released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call was held on January 23, 2026, to discuss the company's financial performance and operational updates. This disclosure is part of the mandatory regulatory requirements under SEBI (LODR) Regulations, 2015. Investors can access the recording via the company's website to gain insights into management's outlook and strategic commentary.

Audio recording for Q3 and 9M FY26 earnings call is now publicly available.
The conference call was conducted on January 23, 2026.
Compliance filing under Regulation 30 and 46 of SEBI LODR Regulations.
Direct link to the recording provided: https://www.cipla.com/audio/14467.

💡 Investors should listen to the recording to understand management's perspective on margin sustainability and USFDA status. No immediate action is required as this is a routine compliance update.

Cipla Announces New Leadership Team and KMP Changes Effective April 1, 2026

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 23 Jan 2026, 02:17 PM

Cipla Limited has announced a transition in its Key Managerial Personnel (KMP) and authorized officers, effective from April 1, 2026. The Board has designated Mr. Achin Gupta as the Managing Director and Global CEO, while Mr. Ashish Adukia will serve as the Global CFO. These individuals, along with the Company Secretary and Global General Counsel, are authorized to determine the materiality of events for SEBI disclosures. The announcement follows a board meeting held on January 23, 2026, ensuring a planned leadership succession for the pharmaceutical giant.

Mr. Achin Gupta appointed as Managing Director and Global CEO effective April 1, 2026
Mr. Ashish Adukia designated as the Global Chief Financial Officer
Ms. Meera Vanjari (Global General Counsel) and Mr. Rajendra Chopra (CS) included in the authorized KMP list
Changes are made under Regulation 30(5) of SEBI Listing Regulations for materiality disclosures
The board meeting approving these changes concluded at 2:00 p.m. IST on January 23, 2026

💡 Investors should monitor the transition for any changes in corporate strategy or capital allocation under the new leadership. No immediate action is required as the effective date is over two months away.

Cipla Re-appoints P R Ramesh as Independent Director for Second 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 23 Jan 2026, 02:09 PM

Cipla's Board has approved the re-appointment of Mr. P R Ramesh as an Independent Director for a second five-year term starting July 1, 2026. Mr. Ramesh, a former Deloitte India Director with over 45 years of experience, currently chairs the company's Audit Committee. This move ensures continuity in governance and financial oversight, as he also serves on boards of other major firms like L&T and Nestlé India. The appointment is subject to shareholder approval and will extend his tenure until June 30, 2031.

Re-appointment of Mr. P R Ramesh for a second 5-year term from July 2026 to June 2031
Mr. Ramesh brings over 45 years of experience in audit, risk services, and finance
He currently serves as the Chairman of the Audit Committee at Cipla
The director also holds board positions at blue-chip companies including Nestlé India and L&T

💡 No immediate action is required as this is a routine governance matter ensuring continuity. Investors should view the retention of an experienced audit professional as a positive sign for corporate governance.

Cipla Re-appoints P R Ramesh as Independent Director for Second 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 23 Jan 2026, 02:06 PM

Cipla's Board has approved the re-appointment of Mr. P. R. Ramesh as an Independent Director for a second five-year term starting July 1, 2026. Mr. Ramesh, a former Deloitte Director with over 45 years of experience, currently chairs the company's Audit Committee. His extensive background in finance and governance across major firms like Nestlé and L&T provides continuity in oversight. The appointment is subject to shareholder approval and will extend his tenure until June 30, 2031.

Re-appointment for a second 5-year term from July 1, 2026, to June 30, 2031
Mr. Ramesh has over 45 years of experience in audit and risk services
Currently serves as the Chairman of the Audit Committee at Cipla
Holds board positions in other major firms like Nestlé India and Larsen & Toubro

💡 This is a routine governance update ensuring leadership continuity; no immediate action is required. Investors should view this as a positive sign of stable corporate oversight.

Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr; EBITDA Margins Contract to 17.7%

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 01:44 PM

Cipla reported a challenging Q3 FY26 with flat revenue growth of 0.02% YoY at ₹7,074 crore. Profitability took a significant hit as EBITDA fell 36.9% to ₹1,255 crore and PAT plummeted 57% to ₹676 crore, impacted by rising material costs and exceptional items. While the India business showed resilience with 10% growth in branded prescriptions, the North America segment faces temporary headwinds due to a manufacturing pause for Lanreotide. The company maintains a very strong balance sheet with a net cash position of ₹10,229 crore.

Revenue remained nearly flat at ₹7,074 crore compared to ₹7,073 crore in Q3 FY25.
EBITDA margins compressed significantly to 17.7% from 28.1% in the previous year's quarter.
One India business contributed 49% of total revenue, with Respiratory therapy outperforming the market by 400+ bps.
North America revenue stood at $167 million, with Albuterol maintaining a #1 market share of 22%.
Net cash position strengthened to ₹10,229 crore, providing significant capital for strategic M&A like the Inzpera acquisition.

💡 Investors should monitor the recovery of EBITDA margins and the timeline for the re-supply of Lanreotide in the US market. While the India growth story and Pfizer partnership are positive, the sharp decline in quarterly profitability warrants a cautious outlook in the near term.

View All CIPLA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 6.8% YoY to INR 27,547.62 Cr in FY25. The One Africa segment (South Africa, Sub-Saharan, North Africa) delivered a 14% revenue growth reaching INR 3,827 Cr. South Africa specifically saw a 15% increase in local currency to ZAR 6.3 billion. Q2 FY26 revenue reached a record INR 7,589 Cr, up 8% YoY.

Geographic Revenue Split

India (Domestic) contributes 42% of total revenue, followed by the US at 29%, South Africa at 14%, and Emerging Markets & Europe at 12%. This diversification helps mitigate regional economic downturns.

Profitability Margins

Gross margin stood at 67% in Q2 FY26, driven by a favorable product mix. FY25 PBILDT margins improved by 113 basis points to 25.83% due to cost rationalization and operational efficiency. Profit After Tax (PAT) for FY25 was INR 5,272.52 Cr.

EBITDA Margin

EBITDA margin for Q2 FY26 was 25%. However, the full-year FY26 EBITDA margin guidance has been revised downward to 22.75% - 24% (from 23.5% - 24.5%) due to increased R&D investments and the expiry of exclusivity for key products like Revlimid.

Capital Expenditure

Cipla maintains a cautious approach to large-scale capex following its US$ 550 million acquisition of InvaGen in FY16. Current focus is on expanding API R&D and manufacturing capacities to support long-term growth, though specific INR Cr targets for FY26 are not disclosed.

Credit Rating & Borrowing

Maintains a 'Stable' outlook with an overall gearing of 0.02x as of March 31, 2025. Interest coverage ratio improved significantly to 95.58x in Q1 FY25 from 71.11x in FY24, indicating extremely low borrowing costs and high solvency.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) and formulation excipients are the primary raw materials. Material costs accounted for INR 2,498 Cr in Q2 FY26, representing approximately 33% of total revenue.

Import Sources

Sourced globally to support manufacturing units in India (Goa, Indore, Pithampur, Kurkumbh, Patalganga), China, and the US (InvaGen and Central Islip).

Key Suppliers

Not specifically named in the documents, but the company utilizes a mix of in-house API manufacturing and external global partners through in-licensing agreements.

Capacity Expansion

Operating with a portfolio of over 1,500 drug types. Plans include expanding API R&D and manufacturing capacities to enhance vertical integration and yield efficiency.

Raw Material Costs

Material costs rose 9.4% YoY to INR 2,498 Cr in Q2 FY26. The company employs a strategy of cost optimization through process efficiency and yield improvements to maintain a 67% gross margin.

Manufacturing Efficiency

Focus on 'operational excellence' and 'productivity' has led to significant cost optimization. The Bommasandra facility received a VAI (Voluntary Action Indicated) status from USFDA, indicating acceptable compliance.

Logistics & Distribution

Distribution is handled through a global network covering 78 markets, with a strategic focus on deepening penetration in core markets in Europe and Emerging Markets.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth is driven by a strong R&D pipeline (5.6% of revenue), launching 133 new products in FY25, and strategic alliances like the tirzepatide deal with Eli Lilly. The company is also expanding in South Africa's private market, which grew 15% in local currency.

Products & Services

Pharmaceutical formulations and APIs catering to therapeutic segments including anti-infective, cardiac, gynecology, gastrointestinal, respiratory, and oncology.

Brand Portfolio

Yurpeak (tirzepatide), Actor Pharma (OTC brands), and a portfolio of 1,500+ generic and branded drugs.

New Products/Services

Launched 133 products in FY25. Upcoming launches include respiratory assets in Q4 FY26 and the Yurpeak brand for obesity/diabetes management in India.

Market Expansion

Targeting deeper penetration in 'One Africa' and core European markets. The South African business ranks 2nd in the prescription market and 3rd in OTC.

Market Share & Ranking

Ranks 2nd in the South African prescription (Rx) market and 3rd in the OTC segment. It is a market leader in several therapeutic areas like respiratory and anti-infectives.

Strategic Alliances

Exclusive partnership with Eli Lilly to promote and distribute tirzepatide under the brand Yurpeak in India. Increased stake in Cipla (Jiangsu) Pharmaceuticals to 100%.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and anti-obesity medications (GLP-1s). Cipla is positioning itself through the Eli Lilly alliance and increased R&D for respiratory and oncology assets.

Competitive Landscape

Faces intense competition in the US generics market and South African tender business. Competitors include global generic giants and local players in emerging markets.

Competitive Moat

Moat is built on a massive distribution network, a portfolio of 1,500+ drugs, and high R&D barriers in respiratory medicine. Sustainability is supported by a net-debt-free balance sheet and INR 10,800 Cr in cash.

Macro Economic Sensitivity

Sensitive to US healthcare policies and trade tariffs. Global inflation impacts raw material procurement costs, though partially offset by cost rationalization.

Consumer Behavior

Rising popularity of anti-obesity medications is a noted trend; Cipla is addressing this via the Yurpeak launch. Shift toward private market healthcare in South Africa (77% of their revenue) favors branded generics.

Geopolitical Risks

Geopolitical instability and trade protectionism are identified as key threats that could hamper financial stability and business performance in its 78 markets.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA inspections; Goa and Indore plants currently have pending observations. Compliance with NPPA (National Pharmaceutical Pricing Authority) in India is a critical monitorable.

Environmental Compliance

Upgraded to 'A' from 'BBB' in MSCI ESG Ratings. Featured in the Sustainable Business COP (SB COP) for energy transition initiatives.

Taxation Policy Impact

Effective tax rate is not explicitly stated, but the company reported a consolidated PAT of INR 5,272.52 Cr on a PBT of INR 6,820.81 Cr for FY25.

Legal Contingencies

Pending litigation with the NPPA regarding drug pricing is a key risk. Crystallization of this liability could impact the financial profile, though current liquidity is adequate to cover contingencies.

⚠️ Risk Analysis

Key Uncertainties

USFDA regulatory actions (Import Alerts/Warning Letters) could impact 29% of revenue. Pricing pressure in the US generics market and potential US trade tariffs are major uncertainties.

Geographic Concentration Risk

42% of revenue is concentrated in India and 29% in the US, making the company highly sensitive to regulatory changes in these two jurisdictions.

Third Party Dependencies

Relies on in-licensing partners for several high-growth products; however, no single supplier dependency is cited as a critical risk due to diversified sourcing.

Technology Obsolescence Risk

Mitigated by a 1,700-strong R&D team and a 5.6% R&D-to-revenue spend focusing on next-generation respiratory and oncology treatments.

Credit & Counterparty Risk

Liquidity is strong with INR 10,800 Cr in cash and liquid investments. Working capital utilization is low, and the current ratio of 4.26x indicates excellent receivable quality.